Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst
Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst
On Tuesday, Amgen Inc. (NASDAQ:AMGN) reported second-quarter sales of $8.39 billion, up 20% year over year and beating the consensus of $8.33 billion.
周二，安进股份有限公司（纳斯达克：AMGN）报告了第二季度销售额为839亿美元，同比增长20％，超过了833亿美元的共识。
Product sales grew 20%, driven by 26% volume growth, partially offset by a 3% lower net selling price.
产品销售额增长20％，其中成交量增长26％，部分抵消3％的净销售价格下降。
Excluding sales from the Horizon Therapeutics acquisition, product sales grew 5%, driven by 10% volume growth.
除了Horizon Therapeutics收购的销售额，产品销售额增长了5％，成交量增长了10％。
Twelve products delivered at least double-digit sales growth in the second quarter, including Prolia (denosumab), Evenity (romosozumab), Repatha (evolocumab), Tezspire (tezepelumab), Blincyto (blinatumomab), and Tavneos (avacopan).
第二季度12款产品的销售额增长率均达到两位数，包括普罗利亚（去甲肝纳珠单抗），Evenity（罗莫珊单抗），Repatha（依伦肝素酯） ），Tezspire（特色佩卢单抗），Blincyto（布利那单抗）和Tavneos（avacopan）等。
Related: Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal.
相关：安进通过280亿美元的Horizon收购寻求扩大美国自身免疫性疾病药物的批准。
The company reported adjusted EPS of $4.97, missing the consensus of $5.01.
公司报告的调整后每股收益为4.97美元，低于5.01美元的共识。
Guidance: Amgen expects fiscal year 2024 adjusted EPS of $19.10-$20.10 compared to the consensus of $17.87.
预测：安进预计2024财年调整后每股收益为19.10-20.10美元，而共识为17.87美元。
The company forecasts 2024 revenues of $32.8 billion-$33.8 billion versus the consensus of $30.3 billion.
公司预测其2024年收入为328亿-338亿美元，而共识为303亿美元。
William Blair sees a significant upside for Amgen stock if the Phase 2 MariTide results demonstrate clear differentiation later this year.
威廉·布莱尔（William Blair）认为，如果第二阶段MariTide的结果在今年晚些时候明显有所区别，则安进股票的上涨空间将显著增加。
A Phase 2 study of MariTide is ongoing in adults with overweight or obesity with or without type 2 diabetes mellitus. Topline data are anticipated in late 2024.
MariTide的第二阶段研究正在进行中，对象是体重超标或肥胖的成年人，伴有或不伴有2型糖尿病。顶线数据预计在2024年年底发布。
A Phase 2 trial investigating MariTide for type 2 diabetes in patients with and without obesity is planned to initiate in late 2024.
计划于2024年底开始进行MariTide治疗2型糖尿病患者（有或没有肥胖症）的第二阶段试验。
With shares trading at roughly 17 times the updated 2024 EPS estimate of $19.25, the analyst says there is meaningful room for multiple expansions with continued investor enthusiasm for MariTide's prospects.
该分析师表示，随着股票交易价格约为更新后2024年每股收益预测的17倍25美元，如果继续对MariTide的前景感到热情，将有显著的多重扩张空间。
"Additional pipeline assets, including Imdelltra and rocatinlimab, also have blockbuster potential, and we believe additional Phase 3 readouts with Uplinza expected in the second half of this year have the potential to support the blockbuster potential of that franchise as well," the analyst added.
该分析师补充说：“其他的管道资产，包括Imdelltra和rocatinlimab，也具有亿美元的潜力，而我们认为Uplinza的其他第三阶段读数有望在今年下半年支持该公司积木类的潜力。”。
Amgen faces near-term challenges with legacy products, such as the upcoming biosimilar launch to Prolia and Xgeva in May 2025, and struggles to expand market share with its biosimilars. However, the analyst notes that clinical developments over the next 6 to 12 months offer significant reasons for investor optimism regarding the company's long-term growth prospects.
安进面临着传统产品的短期挑战，例如即将推出Prolia和Xgeva的生物类似物，并且在其生物类似物中推广市场份额。然而，该分析师指出，在未来6至12个月内的临床发展中，投资者对公司长期增长前景的乐观情绪提供了重要的原因。
William Blair reiterates the Outperform rating.
William Blair重申Outperform评级。
Price Action: AMGN stock was down 4.99% at $312.80 at the last check on Wednesday.
价格行动：最后一次交易时，AMGN股票下跌4.99％，至312.8美元。
- CVS Health Reports Mixed Q2 Earnings, Lowers 2024 Outlook, Reshuffles Segment Management.
- 西维斯健康公布Q2财报，业绩表现不俗，2024年前景调低，重组段领导团队。
Photo via Shutterstock
图片来自shutterstock。